OneMedForum New York – Emerging Company ConferenceThe Roosevelt Hotel – June 30, 2010

OneMedForum New York – Emerging Company ConferenceThe Roosevelt Hotel – June 30, 2010

Investor PresentationJune 2010

www.accesspharma.com

This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard™, the sales of, market opportunities for and planned studies of ProLindac™, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Access's Annual Report on Form 10-KSB for the year ended December 31, 2009, and other reports filed by the companies with the Securities and Exchange Commission.

These materials are not an offer to sell securities and are not soliciting an offer to buy securities. 

For Additional Access Pharmaceuticals Information, Go to the Following Publicly Available Resources:

www.AccessPharma.com

at AccessPharma

at Access Pharmaceuticals

2

Safe Harbor Statement

Two Drug Delivery Platforms – Proprietary drug delivery platforms creates multiple product opportunities; mitigates single product/technology exposure.

Deep Late Stage Products – Access has late-stage products, including FDA-approved MuGard, and ProLindac and Thiarabine (through multiple Phase II trials).

Partnering Strategy – Access has completed eight partnerships or collaborations in the past 24 months: upfront payments, royalties, research costs, clinical costs.

Experienced Team – Experienced chemists, pre-clinical and manufacturing experts, clinical development personnel, and business development and finance personnel.

Focus on Shareholder Value – Management and board members are significant shareholders, focused on increasing shareholder value.

3

Corporate Overview & Highlights

Access Pharmaceuticals, Inc. (ACCP.OB) – a drug delivery company with late-stage products for cancer, diabetes and hormone replacement. Several products are based on Access’ proprietary drug delivery platform technologies.

4

Multiple Platforms Drives Opportunity

OncologyPre-

clinical IND Phase 1 Phase 2 Phase 3 ProductPotential

           

MuGard ™ FDA APPROVED >$1B

ProLindac™    ~ $3 B             

Thiarabine™  >$600 M

Diabetes

Cobalamin Oral Insulin Moving toward Proof of Concept in-Man Study >$1B

Hormone / Hormone Replacement

Human Growth Hormone >$1B

Fertility >$1B

Two proprietary, drug-delivery platform technologies enable product development across multiple biotechnology sub-sectors: Cancer, Diabetes, Hormone, Fertility, etc..

5

MuGard – FDA-approved cancer supportive care product

6

MuGard™ - Treating A Significant Health Issue

Oral Mucositis: Significant Medical Issue – Often Unrecognized, Undiagnosed and UndertreatedOral Mucositis: Significant Medical Issue – Often Unrecognized, Undiagnosed and Undertreated

Well being PainProblems with eating, drinking,speaking and swallowingWeight lossImpairment of quality of lifee.g. mood

Infection Reduces infection barrier

Compromisedtreatment

Reduced dosageBreaks or delays in therapyaffecting treatment outcomes

Economicimpact

Prolonged hospital staysIncreased use of resources e.g.feeding tube placement

>$1 Billion Addressable Market: Target all cancer

patients; 1.5 million US cancer patients annually

(incidence). Roughly 90% of patients on radiation (43%

severe); and 40% of patients receiving chemotherapy

MuGard Stands Alone: Only FDA-approved product

that instructs pre-treatment; Safe to swallow

Multiple Marketing Partners: Partners signed for EU,

Switzerland, Norway, Iceland, China, Korea; US

manufacturing completed – launch activities commencing

Royalties: 20%, scaling to 25%

7

MuGard™ - Oral Mucositis (OM)

European Launch Underway; North American / Far East Launch SoonRoyalties Start This Year

European Launch Underway; North American / Far East Launch SoonRoyalties Start This Year

8

Indications: dryness or dry mouth associated with various conditions

Directions for use: Swish and spit out.

Indications: indicated for the management of pain and relief of pain…

Directions for use: Gargle and spit out.

Indications: “Magic Mouthwash" prepared by pharmacists and used to treat mouth sores (oral mucositis)

Directions for use: Gargle and spit out

Indications: MuGard is indicated for the management of oral mucositis/ stomatitis

Directions for use: … rinse may be expelled or swallowed … safe to swallow …

…recommended that patients purchase MuGard™ prior to the commencement of cancer therapy ..

MuGard is recommended for preventative use

MuGard can be swallowed to coat lesions in throat

MuGard’s Industry Leading Label

Manufacturing of MuGard (Accupac) – product manufactured and ready to ship

Key opinion leader collaboration (Dr. Stephen Sonis) – Oral Mucositis expert

MuGard Centers-of-Excellence Program – targeting large oncology networks to build

awareness and clinical experience with MuGard

Work with reimbursement consultants – filed reimbursement coding application and

discussions are ongoing with major third-party payers

Key Clinical Data – presented last week at MASCC and ongoing throughout the year;

supports prevention, treatment, pain relieve, ease-of-use

Secure additional distribution channels

Long-term stability for full commercial availability – on schedule for late July

Additional MuGard partnerships

MuGard - US Commercial Launch Activities

9

ACCP Remains On-track for Full-Scale North American MuGard Launch

10

Cobalamin – oral drug delivery platform to enhance absorption of large molecules

11

Cobalamin Oral Drug Delivery Platform

12

3

4

The nanoparticle coatedwith Cobalamin (red)binds to intrinsic factor (1),which in turn binds to itscell surface receptor (2).

The nanoparticle coatedwith Cobalamin (red)binds to intrinsic factor (1),which in turn binds to itscell surface receptor (2).

The nanoparticle is transported across thecell (3), crosses the gutwall and enters the bloodstream (4).

The nanoparticle is transported across thecell (3), crosses the gutwall and enters the bloodstream (4).

Using The Body’s Own Vitamin B-12 Absorption SystemTo Enable and Enhance Delivery of Drugs Through Gut Wall

The “Trojan Horse” Delivery Vehicle

Using The Body’s Own Vitamin B-12 Absorption SystemTo Enable and Enhance Delivery of Drugs Through Gut Wall

The “Trojan Horse” Delivery Vehicle

Nanopolymer “payload” can beInsulin, growth hormone, EPO, etc.

Nanopolymer “payload” can beInsulin, growth hormone, EPO, etc.

Cobalamin Oral Insulin – Access has achieved unprecedented levels of oral bioavailability of insulin in two animal models ( >80% of that achieved by injection).

Two Ongoing Collaborations – Oral insulin provided to two collaborators that have confirmed high levels of oral bioavailability with Cobalamin oral insulin

Cobalamin Human Growth Hormone – Demonstrated high oral bioavailability and a 25% improvement in weight gain in standard animal model

Multiple Applications – Ongoing discussions with multiple potential partners looking at exploiting Cobalamin oral drug delivery for insulin, HGH, fertility drugs, proteins, etc.

Patent Life-cycle Management Tool –protect patent (IP) position through cobalamin formulation of existing drugs, resulting in new IP

Phase I Human Trial – Moving Cobalamin oral insulin into a proof-of-concept Phase 1 study in man

sRNAi – Adaptation of Cobalamin system to provide delivery vector for sRNAi therapeutics being evaluated; partnering and collaboration discussions ongoing

12

Significant Oral Bioavailability

Multiple Collaborations Driving Enhanced Data Set;Planning Initiation of Phase I Human Trial in Cobalamin Oral Insulin

Multiple Collaborations Driving Enhanced Data Set;Planning Initiation of Phase I Human Trial in Cobalamin Oral Insulin

13

ProLindac – Phase II cancer drug for solid tumors

ProLindacTM – Access designed a second generation DACH platinum using our proprietary nano-polymer expertise.

Eloxatin®

• FDA approved (2001) for front-line metastatic colorectal cancer

• 2008 $2.5+ billion projected sales globally• Significant neurotoxicity

Partnering On-going – Partnered with Aosaikang Med Group (ASK) in China and JCOM in Korea. Partners paid upfront, committed to run 3 clinical trials that ACCP controls, and royalties.

14

ProLindac™

Positioning ProLindac™ as a Replacement for Sanofi-Aventis’ EloxatinRepresents a $3+ Billion Market Opportunity

Positioning ProLindac™ as a Replacement for Sanofi-Aventis’ EloxatinRepresents a $3+ Billion Market Opportunity

DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background

Chelator releases platinum compound in low pH environment; e.g. tumor

Monotherapy in relapsed, platinum-sensitive patients• 36 patients enrolled in six centers in France; final follow-up ongoing• Heavily treated patients (at least 3, up to 7, previous regimens)• Exploring two dosing schedules (once/two weeks and once/three weeks)

Safety – ProLindac Exhibited Very Benign Safety Profile• Patients tolerating drug well through multiple cycles (up to 10 or more)• No Eloxatin-like neurotox; no nephrotox; no hematotoxicity; no worse emesis

Efficacy and Activity – ProLindac “Outperforms” Current Best Care• At highest doses, 66.7% ProLindac patients responded; Activity levels superior to

oxali or carbo in monotherapy in similar but healthier patient populations (approx 20%)

Next Steps • Combination trials: Partners ASK and JCOM paying for three Access-designed and

managed Phase 2/3 trials: ProLindac plus taxol in recurrent ovarian and ProLindac plus Lilly’s Gemzar in liver and pancreatic cancer; additional combination studies possible in other tumor types

• Partnering discussions ongoing

15

ProLindac™ Phase II Trial – Relapsed Ovarian

Final Study Results – Safe and Active DACH Platinum DrugFinal Study Results – Safe and Active DACH Platinum Drug

16

Thiarabine – Phase II cancer drug for Leukemias and Lymphomas

New Nucleoside Analogue – Same class as other clinically successful FDA approved

nucleoside analogues such as fludarabine and cladrabine; Clofarabine was approved

after a single 44 patient study.

Significant Data/Information Known – Drug was well tolerated and active in two Phase 2

clinical trials in advanced solid tumors. Significant clinical pharmacology and dose

scheduling information known.

MD Anderson Cancer Center – Principal investigator is Hagop Kantarjian, M.D., Head of

Leukemia Dept. at MD Anderson (same team of experts that have successfully led to

approved nucleoside analogues in leukemias and lymphomas).

Clinical Plan – Pre-clinical and clinical studies indicate strong potential in leukaemia or

lymphoma. Based upon clinical data, ACCP is finalizing trial designs and protocols in AML,

ALL, and B-cell lymphomas.

17

Thiarabine – A Novel Nucleoside Analogue

Significant Clinical Data Available – Ready for Phase II TrialsSignificant Clinical Data Available – Ready for Phase II Trials

SpePharm, B.V. – MuGard marketing partner in European Union; rolling launch of MuGard ongoing in UK, Germany, Italy, Nordic countries, Greece; anticipated launches in France, Benelux, Spain and throughout EU continues.

Aosaikang Medicinal Group (ASK) – Rights to ProLindac in greater China; provides second source manufacturing; obligated to pay for two controlled combination studies

JCOM Ltd – Rights to ProLindac in Korea; obligated to pay for one pivotal controlled combination study.

JCOM Ltd – Rights to MuGard in Korea; securing regulatory approval and preparing commercial launch in 2010

RHEI Pharma: – Rights to MuGard in greater China; securing regulatory approval, and seeking source of supply; preparing for commercial launch

US Large Pharma – Sponsored research agreement evaluating cobalamin oral drug delivery platform (insulin and human growth hormone)

US and European Biotechnology Company – Material transfer agreement and collaboration agreement; evaluating cobalamin oral insulin in animal models

18

Active Partnering Strategy For Drug Programs

Active Business Development Effort; Securing Partnerships andCollaborations to Enhance Value and Share Costs

19

Jeffrey B. Davis, Chief Executive Officer: President, SCO Financial Group LLC; Sr. VP and CFO of a healthcare technology company; VP, Corporate Finance, at Deutsche Morgan Grenfell; Senior marketing and product management positions at AT&T Bell Laboratories; Marketing and Product Manager at Philips Medical Systems North America. MBA, The Wharton School, University of Pennsylvania; BS Biomedical Engineering, Boston University.

Esteban Cvitkovic, M.D., Vice Chairman, Senior Director, Clinical Oncology R&D: Board-certified oncologist with over 30 years experience in oncology therapeutics, including clinical research, clinical pharmacology, design of single-agent and combination regimens, and optimization of clinical efficacy; played a fundamental role in the registration strategy and post-registration development of cisplatin and oxaliplatin; held staff and academic appointments at Memorial Sloan Kettering Cancer Center (NY), Columbia Presbyterian (NY), Hospital St. Louis (Paris), Instituto Mario Negri (Milan) and Institut Gustave Roussy (Villejuif).

Frank Jacobucci, Vice President Sales & Marketing: Over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.

David P. Nowotnik, Ph.D., Senior Vice President Research and Development: Senior Director, Product Development, Guilford Pharmaceuticals, Inc.; Group Leader, Bristol-Myers Squibb. Section Leader, Amersham International. Research Chemist, Tate and Lyle and Aspro-Nicholas. PhD, Organic Chemistry, University of London.

Stephen B. Thompson, Vice President and CFO: Controller and Administration Manager, API; Controller, Robert E. Woolley, Inc., a hotel real estate company; Controller, OKC Limited Partnership, an oil and gas company. Accounting and finance, Santa Fe International Corporation.

Phillip Wise, Vice President Business Development and Strategy: VP, Commercial and Business Development and CFO, Enhance Pharmaceuticals; VP, Commercial and Business Development, Ardent Pharmaceuticals; Director of Managed Care Marketing & Director of New Product Planning, Glaxo Wellcome; MBA, University of Virginia; BS, Industrial and Systems Engineering, Georgia Institute of Technology.

Experienced Management Team

Steven H. Rouhandeh, ChairmanSteve Rouhandeh is a Chief Investment Officer of SCO Capital Partners, L.P., a New York based life sciences fund.  Steve also is a founder of SCO Financial Group LLC, a highly successful value-oriented healthcare group with 11-year track record in sector (advisory, research, banking and investing). Steve possesses a diverse background in financial services that includes experience in asset management, corporate finance, investment banking and law.

Esteban Cvitkovic, M.D., Vice Chairman – see Management

Mark Ahn, Ph.D.Dr. Ahn is currently Professor and Chair of the Science & Technology Entrepreneurship Faculties of Commerce & Administration and Science at the Victoria University of Wellington, in Wellington, New Zealand. Previously, Dr. Ahn was President and CEO of Hana Biosciences, Inc., and earlier, Vice President Hematology at Genentech, Inc. where he was responsible for Rituxan. Prior to that, Dr. Ahn held senior positions at Bristol-Myers Squibb, Amgen and FMC Corporation.

Mark AlvinoMark Alvino is a Managing Director at Griffin Securities, a leading provider of corporate finance advisory and brokerage services to the life sciences industry. Prior to that, Mark was a Managing Director for SCO Securities, and additionally held several senior management positions within the investment banking and investor relations industries

Stephen B. Howell, M.D.Dr. Howell is Professor of Medicine, University of California at San Diego, and has extensive experience in platinum therapeutics. Dr. Howell is also a Director of Clinical Investigation and Development Therapeutics Program, UCSD Cancer Center, and has previously received the Milken Foundation prize for contributions to cancer chemotherapy.

Jeffrey B. Davis, Chief Executive Officer – see Management

20

Board of Directors

Strong Board of Directors with Relevant ExperienceStrong Board of Directors with Relevant Experience

Ticker: ACCP (OTCBB)

Applying to Nasdaq and NYSE-AMEX exchanges

Capital Structure

Common shares outstanding 15.4 million shares

Common under preferred shares 9.9 million shares

Total common shares 25.3 million shares

Debt: $5.5 million note due end 2011, convertible at $27.50 per share.

Cash Burn: Roughly $4 million annually. With current cash on balance sheet and expected

upfront and milestone payments, Access has sufficient cash into 2011.

High Quality Institutional Investors: Includes SCO Capital Partners, Oracle Partners, Ramius,

CSFB, Schroeder’s Bank

21

Financial Overview

Achieve scale-up manufacturing of MuGard (Accupac)

MuGard approval in Korea

bioRASI collaboration (Cobalamin first-in-man trial)

Key opinion leader collaboration (Dr. Stephen Sonis)

North American / Far East launches of MuGard

Additional MuGard clinical data, ongoing and at MASCC

Additional MuGard partnerships

Cobalamin preclinical data; additional partnerships and collaborations

Launch Phase 1 Cobalamin oral insulin trial

Initiate ProLindac combination Phase 2 trial; data available

Seek global or regional partnerships for ProLindac (discussions ongoing)

Secure additional investment banking research analyst coverage

22

Milestones / News Flow – 2010 and forward

Significant News Flow Anticipated in 2010 / 2011Significant News Flow Anticipated in 2010 / 2011

Cobalamin Oral Drug Delivery Platform – multiple long term opportunities (oral insulin, oral HGH, fertility drugs,etc.); multiple collaborations ongoing; launch Phase 1 human trial in oral insulin

Late Stage Oncology Pipeline: Proprietary technology has created portfolio of new products for large markets

• One FDA-Approved product, MuGard – North American launch; intro in Europe underway; Asia next; >$1 billion opportunity

• One Phase 2/3-ready cancer drug, ProLindac – New form of proven drug, takes direct aim at Sanofi’s $2.5 billion Eloxatin franchise

• One Phase 2-ready cancer drug, Thiarabine – superior version of clinically and commercially successful nucleoside analogue

Commercial Strategy: Multi-local development and marketing partners to shift risk and share costs, while retaining very attractive revenue/royalty rights.

Value Visibility: Seek “re-listing” on national exchange; actively present company to the investment community.

23

Conclusions – Investment Highlights

ACCP – An Undervalued Investment OpportunityACCP – An Undervalued Investment Opportunity